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1. Introduction 
Inclusion body myopathy associated with Paget’s disease of the bone and frontotemporal 
dementia (IBMPFD, OMIM 167320) is an inherited, autosomal dominant, adult onset multi-
disorder, which affects the muscle, bone and the brain (Watts et al., 2004). It is a rare 
condition with unknown worldwide prevalence. Affected individuals may display one or a 
combination of the following three symptoms which, however, are generally not recognized 
until patients are in their 40s or 50s (Weihl, 2011). (1) IBM (Inclusion body myopathy): 
About 90% of all patients develop proximal and distal muscle weakness initially with 
atrophy of the pelvic and shoulder girdle muscles (Kimonis et al., 2000; Kimonis et al., 
2008b; Kovach et al., 2001; Watts et al., 2003). Cellular inclusion bodies and rimmed vacuoles 
are commonly found in these muscle tissues (Kimonis et al., 2008a; Kimonis et al., 2000; 
Watts et al., 2004). Characteristically, two proteins are most frequently found co-localized 
with the inclusion, ubiquitin and TDP-43 (TAR DNA binding protein-43) (Ritson et al., 2010; 
Weihl et al., 2008). Ubiquitin is a signaling molecule that directs protein substrates into a 
variety of cellular pathways, including protein degradation. Misfolded or unwanted 
proteins are labeled with ubiquitin, mostly in the form of polyubiquitin, and targeted for 
degradation (Clague and Urbe, 2010). TDP-43, on the other hand, is believed to be a 
substrate itself for either proteasome or autophagal degradation (Caccamo et al., 2009; Wang 
et al., 2010). Detection of these proteins in the inclusions suggests impairments in the protein 
degradation pathways. (2) PDB (Paget’s disease of the bone): About half of IBMPFD patients 
develop PDB, which is caused by an imbalance in the activities between osteoblasts and 
osteoclasts. (3) FTD (Frontotemporal dementia): Only ~30% of patients develop FTD, which 
is characterized by language and/or behavioral dysfunction. Interestingly, clinical 
manifestation of these symptoms is rather random, and has no clear-cut correlation with 
family history or mutations. Even within isolated families bearing the same genetic 
mutation, individuals can exhibit different symptoms. These heterogeneities in clinical 
presentations cause frequent misdiagnoses of IBMPFD patients (van der Zee et al., 2009). 
Accurate diagnosis of IBMPFD often requires molecular genetic testing, in addition to a 
combined clinical diagnosis of myopathy, PDB and FTD. 
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2. What is p97? 
In the year 2000, IBMPFD was recognized as a genetically distinct clinical syndrome 
(Kimonis et al., 2000) and was subsequently linked to heterozygous missense mutations in a 
highly abundant cellular protein called p97 (also called valosin-containing protein, VCP) 
(Watts et al., 2004). P97 belongs to the family of AAA+ proteins (ATPases Associated with 
various cellular Activities), which use the energy from hydrolyzing ATP to drive mechanical 
work necessary for a host of functions including homotypic membrane fusion, cell cycle 
regulation and protein degradation (Wang et al., 2004; Woodman, 2003; Ye, 2006). The 
multi-functionality of p97 is consistent with its embryonic lethality when the p97 gene or its 
homologs are disrupted or knocked-out in the mouse, in yeast, in trypanosomes, and in 
Drosophila (Frohlich et al., 1991; Lamb et al., 2001; Leon and McKearin, 1999; Muller et al., 
2007). Moreover, the functional versatility of p97 appears to lie in its ability to interact with a 
large variety of adaptor proteins. For instance, binding to the protein p47 incorporates p97 
in the membrane fusion pathway (Kondo et al., 1997), whereas the p97-Ufd1-Npl4 complex 
participates in ER associated degradation (ERAD) (Richly et al., 2005). So far, more than 
twenty adaptor proteins have been identified that interact with p97 (Madsen et al., 2009), 
but detailed molecular mechanisms of these interactions remain elusive.  
3. Structure of p97 
Structurally, p97 is a homo-hexamer, each subunit (806 residues) consisting of three 
domains: a unique N-terminal domain (N-domain) followed by two conserved AAA+ 
ATPase domains (D1- and D2-domain) in tandem (DeLaBarre and Brunger, 2003; Huyton et 
al., 2003) (Fig. 1A). The N-domain (residues 1-184) contains two sub-domains, an N- 
terminal double -barrel and a C-terminal four-stranded -barrel, and is responsible for 
interacting with most adaptor proteins as well as with protein substrates. Both the D1- 
(residues 211-463) and D2-domains (residues 483-762) are typical AAA+ ATPase domains 
comprised of two sub-domains: a large N-terminal RecA-like domain with an / fold and 
a smaller C-terminal -helical bundle domain. The D1-domain is essential for 
hexamerization of p97 subunits (Wang et al., 2003) and the hexameric ring formation is 
predominantly mediated through interactions between the RecA-like sub-domains (Fig. 1B). 
However, unlike many members of the AAA+ family proteins such as the E. coli ClpA 
unfoldase, the hexamerization of p97 subunits does not require the binding of nucleotide 
(ADP or ATP) at D1-domains, though it has been shown that nucleotide binding does 
accelerate p97 hexamer formation (Singh and Maurizi, 1994; Wang et al., 2003).  Most of the 
ATPase activities of p97 involve the D2-domain, presumably required for the processing of 
substrates (Song & Li, 2003).  
Connecting the domains are loops that have been shown to play important functions. The 
N-D1 loop is 27 residues long and is embedded at the interface between the N-domain and 
the D1-domain. The short peptide stretch (residues 763-806) immediately following the D2-
domain is another region for adaptor protein binding. Although not as common as the N-
domain, this C-terminal tail has been shown to interact with a number of proteins, such as 
Ubxd1 (Allen et al., 2006; Madsen et al., 2008). Similar to other Type-II AAA+ assemblies, the 
p97 assembly was revealed by electron microscopy (EM) and crystallography to be a two-
tiered concentric ring encircling a central pore or axial channel (Fig. 1B). The N-domains are 
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attached to the periphery of the D1 ring, making one ring appear larger than the other. The 
central pore does not run unrestricted through the hexamer, but has a narrowing or a 
constriction point that is formed by a bound zinc ion (DeLaBarre and Brunger, 2003). 
 
Fig. 1. Structure of p97 (A) Domain organization of the full-length p97. (B) Ribbon 
representation of the crystal structure of p97 based on PDB: 1OZ4. Domains are color-coded 
using the scheme in (A) and two views are presented. (C) Locations of IBMPFD mutations 
are shown in the context of the p97 N-D1 structure (PDB: 1E32), which has the D1-domain 
bound with ADP. The IBMPFD mutations are represented by yellow balls. Thirteen 
positions representing twenty mutations are presented. 
4. Mutations in p97 associated with IBMPFD 
So far, only single amino acid substitutions in p97 have been identified from all the clinical 
IBMPFD specimens examined. Altogether, twenty missense mutations found in 13  
different amino acid positions in p97 have been reported to be associated with the disease 
and the majority of them involve substitutions of arginine residues (Table 1) 
(http://www.molgen.ua.ac.be/FTDMutations). While more than half of these mutations are 
located in the N-domain (Ile27, Arg93, Arg95, Pro137, Arg155, Gly157 and Arg159), a few are found 
in the N-D1 linker region between the N- and D1-domains (Arg191 and Leu198) and in the D1-
domain (Ala232, Thr262, Asn387 and Ala439). None has been found in the D2-domain. Among 
these, mutations at Arg155 are the most frequently observed in patients (Table 1). 
Interestingly, mapping these mutations onto the three-dimensional p97 structure in the 
ADP-bound form revealed that they all clustered at the interface between the N- and D1-
domains (N-D1-interface, Fig. 1C).  
5. Wild type vs. IBMPFD mutant p97: Structural characteristics 
Changes in structure as a result of amino acid mutations can lead to a global disruption of 
the protein folding, resulting rapid clearance by cellular stress response mechanisms, or to 
localized structural changes that cause complete loss of the protein function, or to subtle 
conformational changes that alter the function of the protein. Structural changes in mutant 
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proteins can be directly visualized by X-ray crystallography, NMR (nuclear magnetic 
resonance), and EM (electron microscopy) or inferred indirectly by biophysical and 
biochemical methods such as SAXS (small angle X-ray scattering). To understand how 
IBMPFD mutations lead to functional change in p97, it is absolutely necessary to know what 
structural changes these mutations entail. However, knowing what has changed in mutants 
depends heavily on our baseline knowledge of the wild type proteins. 
 
 Change in 
amino acid 
Change in
gene
Location References 
1 I27V 79 A  G
N-
domain 
(Rohrer et al., 2011)
2 R93C 277 C  T (Guyant-Marechal et al., 2006; Watts et al., 2004) 
3 R95C 283 C  T (Kimonis et al., 2008a)
 R95G 283 C  G (Watts et al., 2004)
4 P137L 410 C  T (Palmio et al., 2011; Stojkovic et al., 2009) 
5 R155C 463 C  T (Gidaro et al., 2008; Guyant-Marechal et al., 2006; Schroder et al., 2005; Watts et al., 2004) 
 R155H 463 C  A (Viassolo et al., 2008; Watts et al., 2004) 
 R155P 463 C  C (Watts et al., 2004)
 R155S 463 C  A (Stojkovic et al., 2009)
 R155L 464 G  T (Kumar et al., 2010)
6 G157R 469 G  C (Djamshidian et al., 2009)
  469 G  A (Stojkovic et al., 2009)
7 R159C 475 C  T (Bersano et al., 2009)
 R159H 476 G  A (Haubenberger et al., 2005; van der Zee et al., 2009) 
8 R191Q 572 G  C N-D1 
linker 
(Watts et al., 2004)
9 L198W 593 T  G (Kumar et al., 2010; Watts et al., 2007) 
10 A232E 695 C  A
D1-
domain 
(Watts et al., 2004)
11 T262A 784 A  G (Spina et al., 2008)
12 N387H 1159 A  C (Watts et al., 2007)
13 A439S 1315 G  T (Stojkovic et al., 2009)
Table 1. IBMPFD mutations in p97. 
5.1 Conformational changes in AAA
+
 proteins  
Studies of AAA+ proteins have revealed conformational changes in various domains in 
response to changes in the environment, to substrate binding, and to various bound 
nucleotides. At least some of the observed conformational changes are believed to be 
necessary for function (Vale and Milligan, 2000). N-domains of ClpB were found in different 
positions in crystal structure even though all the subunits were bound with the ATP analog 
AMP-PNP (Lee et al., 2003); this conformational plasticity in N-domains is likely the result 
of different environments each subunit experienced in the crystal and may not be directly 
related to function. By far most of the observed conformational changes, though relatively 
subtle, are induced by binding of various nucleotides in the AAA+ domains. Such 
nucleotide-driven conformational changes have been observed for both Type I (proteins 
with one AAA+ domain) and Type II (proteins with two AAA+ domains) AAA+ proteins in 
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crystal structures such as LTag (SV40 large tumor antigen) (Gai et al., 2004), FstH 
(Bieniossek et al., 2009) and HslU (Wang et al., 2001).  
Conformational changes in AAA+ proteins have been probed by methods other than 
crystallography, which do not depend on obtaining 3-D crystals albeit at relatively lower 
resolutions. Such methods include cryo EM and SAXS. Cryo EM has revealed flexibility in 
the N-domains of E. coli AAA+ protein ClpA (Ishikawa et al., 2004) and SAXS experiments 
have shown large conformational changes in NtrC1 (Chen et al., 2010). Although in some 
cases conformational changes observed with different methods do not completely agree, it is 
widely accepted that AAA+ proteins undergo dynamic movements during their catalytic 
cycle. One general observation relating to structural movements among AAA+ proteins is 
the change in size of the axial pore where substrates enter. The “open-and-close” of the axial 
pore in AAA+ proteins is thought to provide the mechanical force needed to pull the 
substrates through the pore (Kravats et al., 2011; Zolkiewski, 2006).  
5.2 Structural studies of wild type p97  
Crystal structures of wild type p97 have been solved for both the full-length protein and a 
truncated N-D1 fragment (absent of the D2-domain) (DeLaBarre and Brunger, 2003; Huyton 
et al., 2003; Zhang et al., 2000). Although both D1- and D2-domains are capable of 
hydrolyzing ATP (Song et al., 2003), in all the wild type p97 crystal structures determined to 
date, ADP was invariably found in the D1-domains, while either ADP or ADP-AlFx 
(transitional analog) was observed in the D2-domain (DeLaBarre and Brunger, 2003; Huyton 
et al., 2003). These structures share an identical N-domain conformation with the N-domains 
attached to the periphery of the D1 ring, and in plane with it (Fig. 1B). Unsuccessful 
attempts have been made to crystallize wild type p97 with other forms of nucleotides 
trapped in the D1-domain (DeLaBarre and Brunger, 2003). 
On a different front, studies using EM and SAXS to gain structural insights into the 
conformational changes of p97 have revealed rather dramatic changes in the positions of N-
domains (Davies et al., 2005; Rouiller et al., 2002). In contrast to X-ray crystallography, these 
approaches are limited to providing molecular shapes without a clear delineation of bound 
nucleotides. Nevertheless, large conformational changes in the N-domains of p97 can be 
detected by modeling individual domains from crystal structures into these molecular 
envelopes to re-construct structures of p97 under various conditions, although lacking 
absolute certainty. In the presence of different nucleotides (ATP or ADP) and their non-
hydrolysable or transitional analogs (ADP-AlFx, AMP-PNP or ATPS), the N-domains of 
p97 were shown to undergo some of the most dramatic movements during the ATP cycle. 
Although some changes observed by different methods or in different laboratories were not 
always compatible with each other, it is generally agreed that N-domains of p97 are 
conformationally flexible. EM studies of p97 complexed with the adaptor protein p47 also 
showed the N-domains undergoing a large conformational change in the presence of 
different nucleotides (Beuron et al., 2006). However, conflicting results were reported in 
these low-resolution studies on the direction of the N-domain movement in response to 
binding of different nucleotides. An intrinsic difficulty with these studies is the uncertainty 
concerning the nucleotide states at the AAA+ ATPase domains due to the resolution limits of 
these methods. Compounding these problems, it has been known that at least half of the 
nucleotide-binding sites in the D1-domains of p97 are pre-occupied by ADP molecules, 
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which are very difficult to remove (Briggs et al., 2008; Davies et al., 2005). Clearly, high-
resolution structures of p97 in different nucleotide states are needed to unambiguously 
define the relationship of N-domain conformation with nucleotide-binding states.  
5.3 Crystallographic studies of IBMPFD mutant p97 
Recently, a new conformation of N-domains was observed by X-ray crystallography at 2 Å 
resolution with ATPS (a non-hydrolysable ATP analog) bound at the D1-domains of two 
IBMPFD-associated p97 N-D1 mutants, R155H and R95G; both are N-domain mutations (Tang 
et al., 2010). With ATPS bound at the D1-domain, the N-domain undergoes a rotational and 
translational movement to adopt a new position, which is in sharp contrast to the “in-plane” 
position with the D1-ring or Down-conformation, as observed previously in the ADP-bound 
form. In this new conformation, the N-domains uniformly occupy a position above the plane 
of the D1-ring or in the Up-conformation (Fig. 2), despite the fact that no detectable changes 
are seen in the N-domain itself due to either the R155H or R95G mutation (Data not shown) 
(Tang et al., 2010). Accompanying the transition of N-domain from the Down- to Up-
conformation are two prominent structural rearrangements. One is the transition in secondary 
structure of the linker between N- and D1-domain (N-D1 linker), going from the random coil 
in the Down-conformation to the three-turn -helix in the Up-conformation reminiscent of a 
contracted spring pulling the N-domains out of the planar conformation upon the binding of 
ATPS (Fig. 3A). This novel conformation of p97 demonstrated for the first time the dynamic 
movement of the N-domain at near atomic resolution, although observed in p97 mutants. A 
second change is the re-ordering of the N-terminal fragment that encompasses residues 12 to 
20, which was disordered in the ADP-bound structures (Fig. 3B). This re-ordering of the N-
terminal peptide apparently protects the Lys18 from limited proteolysis by trypsin seen in the 
ADP form of p97 (Fernandez-Saiz and Buchberger, 2010). 
 
Fig. 2. Changes in N-domain conformation in response to binding of different 
nucleotides to the D1 domain Ribbon diagrams showing the two N-domain conformations 
of p97 N-D1 obtained from crystal structures. The N-domains, D1-domains and the IBMPFD 
mutations are colored in magenta and blue ribbons and in yellow balls, respectively.  
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Fig. 3. Observed structural re-arrangements in the N-D1 linker and N-terminal peptide in 
response to binding of different nucleotides in the D1-domain (A) The secondary 
structure of the N-D1 linker undergoes a transition from a random coil to a three-turn helix 
as the N-domains move from the Down- to Up-conformation. A close-up view shows the 
two conformations of the N-D1 linker (in green) in the ADP-bound form (Down-
conformation) and in the ATPS-bound form (Up-conformation) of p97 N-D1. The 
nucleotides are represented by sticks with carbon atoms in yellow, oxygen in red, nitrogen 
in blue, phosphorous in orange, and sulfur in gold. (B) The reordering of N-terminal peptide 
Leu12 to Lys20 in the ATPS-bound form (Up-conformation) is represented by stick model. 
The rest of the N-domain and D1-domain are shown as magenta and blue surfaces, 
respectively.  
The above observation appears to favor the hypothesis that the Up and Down movement of 
N-domains is nucleotide dependent because the binding of ADP at the D1-domain of p97 
results in a Down-conformation while binding of ATPS leads to an Up-conformation. 
However, this nucleotide-driven movement may be arguable, as these two conformations 
were observed in two different systems – the wild type in ADP form and the IBMPFD 
mutants in ATPS form. A subsequent structure determination using the same IBMPFD 
mutant and ADP showed that N-domains adopt the Down-conformation, just as the wild-
type p97 in the presence of ADP (Tang et al., 2010), thus unequivocally confirming the 
dependency of N-domain conformation on the nucleotide binding states at the D1-domain.  
5.4 Small angle X-ray scattering (SAXS) studies of wild type and IBMPFD mutant p97 
in solution 
Why crystallographic studies on wild type p97 can only reveal the Down-conformation, 
whereas IBMPFD p97 mutants can be crystallized in both Up- and Down-conformations was 
a paradox. One possible interpretation was that wild type and mutant p97 differ in 
nucleotide binding properties. Alternatively, this could be a crystallization effect. To 
investigate this, we performed SAXS experiments to identify conformational changes in 
IBMPFD mutants in solution. The results clearly demonstrated that in solution IBMPFD 
mutants undergo a nucleotide-dependent N-domain conformational change that is 
consistent with the Up- and Down-conformations observed in the crystals (Fig. 4). By 
serendipity, another major finding from this experiment was that wild type p97 also 
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undergoes a similar nucleotide-driven conformational change as observed in IBMPFD 
mutants (Fig. 4) (Tang et al., 2010). Therefore, the lack of success in crystallizing the Up-
conformation of wild type p97 suggests the presence of an intrinsic conformational 
heterogeneity or asymmetry in the N-domains of the homo-hexamer. 
 
 
Fig. 4. Nucleotide-driven conformational changes in solution observed by SAXS  Distance 
distribution functions, p(r), of p97 N-D1 normalized to a common total probability for wild 
type and mutant N-D1 fragments in the presence of ADP (solid line) ADP and ATPS 
(dashed line). The calculated distribution (Glatter, 1980) is shown of the left based on the 
crystal structure in the absence of bound solvent molecules.  
5.5 ADP and ATPS binding at the D1-doamin 
Although the binding of ATPS to the D1-domain triggers a dramatic movement of the N-
domain, the immediate vicinity of the D1 nucleotide-binding site shows only limited 
perturbations (Tang et al., 2010). When C atoms of the wild type and mutant N-D1 are 
superimposed, the adenosine moieties of the bound nucleotides align very well and the 
immediate environment around the adenosine moiety shows little change. By contrast, the 
phosphate groups in the alignment between ADP and ATPS forms differ, even though the 
same set of residues are involved in contacting the - and -phosphate in both the wild type 
and mutant structures. The -phosphate in the ATPS structure is stabilized by the ionic 
interaction with a magnesium ion (Mg2+, see below), by hydrogen bonds with Gln348 and 
Lys251, by Arg359, an Arg finger residue from a neighboring subunit, and by two water 
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molecules associated with the Mg2+ ion (Fig. 5). Perhaps due to better diffraction resolution, 
in the mutant structures of p97, a Mg2+ ion is present in the nucleotide-binding site of every 
subunit. The Mg2+ ion is at the center of an octahedral mer-triaquo complex with the 
additional three oxo ligands coming from the side chain of the highly conserved Thr252 and 
from the - and -phosphates.  The acidic residues of the DEXX sequence (Asp304 and Glu305) 
in the Walker B motif make hydrogen bonds with two of the water molecules in the Mg2+ 
coordination sphere and, additionally, Asp304 stabilizes Thr252. As expected, most of the 
changes in the nucleotide-binding environment are a consequence of the introduction of the 
-phosphate. 
 
Fig. 5. ATPS binding vicinity of the D1-domain The nucleotide-binding pocket is located 
at the subunit interface. The two subunits are in different colors, green and gray. The ATPS 
molecule is shown as a stick model with carbon atoms in purple, oxygen in red, nitrogen in 
blue, phosphorous in magenta, and sulfur in yellow. The ATPS molecule is enclosed in a 
difference electron density cage contoured at the 2.5 σ level. The Mg2+ ion is shown as a 
green ball with three coordinating water molecules in red.  
6. Wild type vs. IBMPFD mutant p97: Biophysical and biochemical 
characteristics 
Structurally observed differences in the N-domain conformation of p97 strongly suggest a 
change in nucleotide binding affinities between wild type and IBMPFD mutants, even 
though the binding environment for nucleotide seems unperturbed in mutant p97. The fact 
that mutant p97 can be crystallized in the presence of ATPS suggests a few competing 
hypotheses: one of which is the possibility of IBMPFD mutants acquiring a higher affinity 
for ATPS, leading to an alteration in ATPase activity. Alternatively, IBMPFD mutations 
could lead to a reduced ADP binding affinity. From structural studies, we can readily infer 
that the D1 nucleotide-binding site is seriously affected by IBMPFD mutations. However, 
how mutations at the N-D1 interface influence the D1 or D2 ATPase sites is not clear. 
Measuring the binding affinities of various nucleotides toward either D1 or D2 ATPase sites 
and the ATPase activities of the protein will provide biochemical indications as to how 
IBMPFD mutations might affect the biochemical properties of p97.  
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6.1 Nucleotide-binding affinity and ATPase activity  
As mentioned earlier, p97 has two ATPase domains, D1 and D2; both are capable of 
hydrolyzing ATP. ATPase activity requires the presence of Mg2+ and is stimulated by high 
temperature (Song et al., 2003). While the D2-domain mediates most ATPase activity, the D1-
domain contributes to heat-induced activity (Song et al., 2003). By using isothermal 
calorimetry (ITC) and Walker A mutants of either the D1- or D2-domains, it was shown that 
the binding of both domains to ATPS is similar with dissociation constants in the range of 1 
M, but binding of ADP to the D1-domain is nearly 30-fold higher than that of the D2-domain, 
which is consistent with the higher ATPase activity of the D2-domain (Briggs et al., 2008).  
Because the onset of IBMPFD is relatively late in life, the mutations in p97 are not expected 
to have dramatic defects in function. Indeed, IBMPFD equivalent mutations introduced into 
cdc48, a yeast homolog of p97, did not appear to interfere with normal cell growth (Esaki 
and Ogura, 2010). Although IBMPFD mutation sites are not in the immediate vicinity of the 
ATP-binding sites, as shown by crystal structures of p97, especially in the ATPS bound 
form, reports on how mutations affect ATPase activity of p97 vary. Two reports showed that 
mutants exhibit higher ATPase activity than the wild type to various degrees (Manno et al., 
2010; Weihl et al., 2006). One paper, by contrast, reported no significant alterations in 
ATPase activity of four IBMPFD mutants (Fernandez-Saiz and Buchberger, 2010). Mutant 
p97 also displayed an even higher level of heat-stimulated ATPase activity (Halawani et al., 
2009). 
ITC measurements in N-D1 fragments of p97 showed that instead of predicted higher 
affinity for ATPS in the D1-domain, all mutants showed lowered affinity, up to five-fold 
weaker, towards ADP when compared to the wild type (Table 2) (Tang et al., 2010). More 
interestingly, all mutants displayed biphasic titration profiles toward ATPS, suggesting two 
distinct binding sites, one high and one low affinity site. 
 
N-D1 p97 
ATPS ADP 
Kd (M) N Kd (M) N 
Wild type 0.89 ± 0.28 0.12 ± 0.01 0.88 ± 0.18 0.35 ± 0.06 
R95G 0.13 ± 0.02 0.56 ± 0.01 2.27 ± 0.11 0.62 ± 0.08 
R155H 0.13 ± 0.01 0.61 ± 0.01 4.25 ± 0.54 0.72 ± 0.18 
ITC with ATPS for IBMPFD mutants showed biphasic titration curves and data were fitted with a 2-
site model. The Kd values for mutants are derived from fitting to the first phase. 
Table 2. Dissociation constants (Kd) and binding stoichiometry (N) of wild type and mutant 
p97 N-D1 fragments for ATPS and ADP determined by ITC. 
6.2 Pre-bound ADP in D1 nucleotide-binding sites 
A unique characteristic of p97 was demonstrated by a urea denaturation experiment; the D1 
sites are occupied by a significant portion of pre-bound ADP, which is difficult to release 
without denaturing the protein (Davies et al., 2005). ITC experiments with wild type p97 
confirmed that a fraction of D1 sites are not accessible to nucleotide titration (Briggs et al., 
2008). Consistent with the lowered Kd values for ADP binding in IBMPFD mutants, D1 sites 
were shown to be significantly more accessible to ADP titration by ITC and displayed a 
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biphasic titration curve for ATPS, reflecting the first phase binding of the empty sites and 
the second phase of the pre-bound sites (Table 2) (Tang et al., 2010). Extraction by heat 
denaturation experiments of pre-bound ADP from the D1 sites of p97 supported the 
observation by ITC that the number of titratable sites is inversely related to the amount of 
pre-bound ADP present at the D1-domain (Tang et al., unpublished data). These findings 
suggest that while in wild type p97 a significant number of sites with pre-bound ADP in D1-
domains of p97 are not exchangeable by a different form of nucleotides present in solution, 
IBMPFD mutations have altered the environment and lowered binding affinity for ADP to 
allow exchange, even though the change in the ADP binding site is too subtle to be detected 
by crystal structures.  
A consequence of lowered binding affinity for ADP in the D1-domain of IBMPFD mutants is 
the uniformly increased accessibility of D1 sites to various nucleotides present in solution 
such as ATPS. Indeed, successful crystallization of mutant p97 in the presence of ATPS is a 
result of this effect. On the contrary, the pre-bound ADP molecules in the D1-domains of 
some subunits of wild type p97 do not substitute for ATPS, in spite of having a higher 
affinity towards ATPS than ADP (Tang et al., 2010). Consequently, in the presence of excess 
ATPS in solution, there will be an admixture of ADP- and ATPS-bound D1 sites within a 
hexamer. Thus, the failure to crystallize wild type p97 in the presence of ATPS is a 
manifestation of non-uniformity in binding to nucleotides by different subunits in the D1-
domains of hexameric p97. 
6.3 Changes in interaction with adaptor proteins 
By interacting with various adaptor proteins, p97 is able to play a role in a number of 
important cellular pathways. Therefore, alterations in adaptor protein binding by IBMPFD 
mutants have been investigated in both in vivo and in vitro experiments. Again, results from 
different groups are not completely consistent (Fernandez-Saiz and Buchberger, 2010; 
Manno et al., 2010). Isolated mutant p97 exhibited the same binding as wild type p97 
towards adaptor proteins p47, Ufd1-Npl4, E4B and the human UFD-2 homolog. However, 
mutants showed impaired binding to ubiquitin ligase E4B in the presence of Ufd1-Npl4. In 
vivo pull-down experiments using HEK293 cells showed reduced binding towards the E4B 
and enhanced binding towards ataxin 3, thus resembling the accumulation of mutant ataxin 
3 on p97 in spinocerebellar ataxia type 3 (Fernandez-Saiz and Buchberger, 2010). However, 
similar in vivo studies were done showing enhanced binding of the Ufd1-Npl4 pair by 
IBMPFD mutants but not for p47 (Manno et al., 2010). 
7. Implications concerning p97 function and disease 
One major contribution of p97 to cellular processes is its apparent participation in protein 
quality control and homeostasis, involving the ubiquitin-proteasome degradation pathway, 
ER associated degradation, and formation of autophagosomes. The multifaceted clinical 
presentation of patients with IBMPFD is consistent with the broad spectrum of p97 
functions. Indeed, pathology and the cellular hallmarks such as the accumulation of 
inclusion bodies and rimmed vacuoles of IBMPFD can be reproduced both in cell culture 
and in animal models (Custer et al., 2010; Ju and Weihl, 2010; Weihl et al., 2006; Weihl et al., 
2007). However, the structural and molecular basis of how p97 is involved in these different 
pathways and the mechanism of how p97 mutations lead to dysfunction remain elusive. 
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7.1 IBMPFD mutations produce subtle structural and functional alteration in p97 
Using structural, biophysical and biochemical approaches and through detailed 
comparative study of wild type and IBMPFD mutant p97, details of the molecular 
mechanisms of p97 at the most fundamental level are beginning to emerge. As a late onset 
disease, the IBMPFD mutations in p97 are not expected to dramatically disrupt cellular 
functions. Indeed, as shown from the cell biological, structural and biochemical data, all 
IBMPFD mutants (1) appear to have a normal phenotype at least in the early stage of life in 
cultured cells, in yeast, and in fruit flies, (2) do not have observable structural alterations in 
their constituent domains, as compared to the wild type, (3) can form proper hexameric ring 
structures, (4) have nucleotide-binding pockets indistinguishable from those of the wild 
type, and (5) are able to undergo nucleotide-driven conformational change in solution. 
In spite of these similarities, subtle yet significant differences have also been detected in 
IBMPFD mutants, including (1) overall up-regulated ATPase activities, (2) ability to undergo 
uniform nucleotide-dependent N-domain conformational change that leads to its 
crystallization in the presence of ATPS, (3) lowered binding affinity toward ADP in the D1-
domain, (4) less non-exchangeable pre-bound ADP in the D1-domain, and (5) subtle 
differences in binding of adaptor proteins. 
7.2 Asymmetry in p97 function 
Enigmatic observations concerning the failure of wild type p97 to crystallize in the presence 
of ATPS, yet being able to undergo nucleotide-dependent N-domain conformational 
change in solution suggest the functional importance of the non-uniform binding of 
nucleotides by p97 to the D1-domains and of the asymmetry in N-domain conformations 
among its six subunits. This asymmetry is a built-in property of wild type p97, as 
demonstrated by ITC and heat or urea denaturation experiments with characteristically pre-
bound ADP at the D1-domain. Although a p97 hexamer is formed by six identical 
monomers, a fraction of the D1 sites is always pre-occupied by ADP, which is very difficult 
to release or exchange with other nucleotides. As a result, ATP in solution is only able to 
access the empty D1 sites, which drive the N-domain to the Up-conformation, whereas the 
N-domains remain in the Down-conformation for those subunits with pre-bound ADP. 
Although it is not yet clear how p97 maintains this asymmetry during its catalytic cycle, 
some level of communication must exist among subunits.  
A model for the ATP cycle in the D1-domain and the corresponding N-domain 
conformation has been proposed by integrating the structural and biochemical data of wild 
type and mutant p97 (Fig. 6). The model proposes four nucleotide-binding states for the D1-
domain. (1) There is the “ATP” state with ATP bound and the N-domain in the Up-
conformation.  Crystallographic and X-ray scattering experiments support the existence of 
this state in subunits of both mutant and wild type p97. It should be noted that due to non-
exchangeable, pre-bound ADP in a wild type p97 hexamer, not all subunits can bring their 
N-domains to the Up-conformation, even with an excess of ATP in solution. (2) There is an 
“ADP-locked” state with non-exchangeable, pre-bound ADP at the D1 site and the N-
domain in the Down-conformation. This state appears to be important for wild type p97 
function and the pre-bound ADP is particularly difficult to release. The structure of the N-
D1 fragment of wild type p97 may represent this conformation. (3) The “ADP-open” state is 
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defined by the binding of exchangeable ADP. This state was observed for mutant p97 by its 
biphasic ITC titration profile and is presumably in equilibration with the ADP-locked state. 
The structure of R155H with bound ADP may represent this conformation. (4) Finally, there 
is the “Empty” state with nucleotide-binding sites unoccupied and the N-domain in an 
unknown position. For wild type p97, the transition between the “ADP-locked” and “ADP-
open” states is thought to be tightly controlled, resulting in rare ADP-open states, leading to 
asymmetry in the nucleotide binding and N-domain conformation in a hexameric p97. 
 
 
Fig. 6. Models for the N-domain movement in p97 during ATP cycle Schematic diagram 
for the control of the N-domain conformation in the wild type and IBMPFD associated N-D1 
fragment of p97. Different domains are colored and labeled. The IBMPFD mutations are 
represented by yellow circles. Four states are defined for each nucleotide-binding site in D1: 
Empty, ATP, ADP-locked and ADP-open states, as labeled. The type of nucleotide bound at 
the D1-domain is labeled. Each subunit of the hexameric p97 is assumed to operate 
independently in this model.  
From structural and molecular characterizations, we can infer that the non-uniform 
movement of p97 is essential to its function. In order to generate the up-and-down 
movement of the N-domain in a non-uniform fashion, the “ADP-locked” sites needed to be 
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activated to the “ADP-open” state. It is thought that in wild type p97 control of the 
transition between the ADP-locked and ADP-open state in D1 could be achieved in two 
ways: (1) the binding of adaptor proteins to the N-domain, or (2) the hydrolysis of ATP in 
the D2-domain.  The N-domain was shown to have an influence on the ATPase activity of 
both N-D1 and the full-length p97 ortholog, VAT, as the N-domain-deleted p97 mutants 
have higher ATPase activity (Gerega et al., 2005). The binding of adaptor protein p47 to the 
N-domain was shown to inhibit the ATPase activity of p97 (Meyer et al., 1998). 
Communication between D1 and D2 is also known to exist for p97 and other type II AAA+ 
proteins. For example, it was shown that the absence of D2-domain inhibits the nucleotide 
exchange activity in D1 (Davies et al., 2005). The yeast Hsp104, another type II AAA+ 
protein, displays cooperative kinetics and inter-domain communication for its two ATPase 
domains (Hattendorf and Lindquist, 2002). However, the exact details of these possible 
control mechanisms for the switching of D1 nucleotide states remain elusive. Like many 
AAA+ proteins involved in protein quality control such as E. coli ClpA and yeast Hsp104, 
p97 functions in handling protein substrates to various pathways, which requires the 
presence of the N-domain. Although how p97 handles these substrates has yet to be defined, 
one advantage of asymmetric interaction over symmetric seems that the former ensures 
continuous contacts with the substrates. 
7.3 Loss of asymmetry in IBMPFD mutant p97  
Mapping the IBMPFD mutations to the Down-conformation of p97 reveals the clustering of 
these mutations at the interface between the N- and D1-domains. Site-directed mutagenesis 
of R86A, a residue present at the N-D1 interface but not identified as an IBMPFD mutation, 
showed to possess all the structural and biochemical characteristics of an IBMPFD mutant 
p97 (Tang et al., 2010). This suggests that the N-D1 interface residues are critical for the 
proper function of p97 by providing tight regulation of the movement of the N-domain and 
the nucleotide state of the D1-domain. 
Instead of prominent structural changes, IBMPFD mutations introduce subtle modifications 
to p97, apparently disrupting communication among the monomers. Unlike the wild type 
p97, IBMPFD mutants allow easy displacement of pre-bound ADP at the D1-domain by 
ATPS, resulting in a unified nucleotide state, and hence, a symmetric hexamer in the Up-
conformation.  Using the same ATP catalytic cycle model for the D1-domain shown above, it 
was postulated that the difference between the wild type and mutants lies in the transition 
between the “ADP-locked” state and the “ADP-open” state. While this transition is tightly 
regulated in wild type p97, this control mechanism is altered in IBMPFD mutants, leading to 
a high concentration of subunits in the “ADP-open” state (Fig. 6). Consequently, p97 
mutants undergo a uniform N-domain conformational change in response to high 
concentrations of ATPS, leading to a defective enzyme. 
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